MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.270
-0.030 (-2.31%)
Aug 13, 2025, 4:00 PM - Market closed
MediciNova Employees
MediciNova had 13 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$858,396
Market Cap
62.29M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MNOV News
- 13 days ago - MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million - GlobeNewsWire
- 21 days ago - MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials - GlobeNewsWire
- 4 months ago - MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025 - GlobeNewsWire
- 4 months ago - First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients - GlobeNewsWire
- 8 months ago - MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND - GlobeNewsWire
- 9 months ago - MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver - GlobeNewsWire
- 9 months ago - MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis - GlobeNewsWire
- 10 months ago - MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) - GlobeNewsWire